Provided by Tiger Trade Technology Pte. Ltd.

Yesterday's Top Gainers

804.23
-13.4665-1.65%
Number of Gainers:18
Number of Losers:33
Number of Flat:3
PE:- -
High:820.27
Open:817.70
Low:801.06
Close:817.69
Volume:79.71M
Turnover:1.23B
Market Cap:137.75B
Float Cap:84.69B

Loading ...

Centrus Hosts Ohio Gov. DeWine, JobsOhio at Piketon Uranium Enrichment Facility

Reuters
·
2 hours ago

Bridgford Foods FY26 Q3 Net Loss Widens to $7.78 Million; Net Sales Drop 9.5% to $47.02 Million

Reuters
·
3 hours ago

MEC Forecasts $50 Million-$60 Million in 2026 Datacenter, Critical Power Cross-Selling Revenue

Reuters
·
3 hours ago

Weatherford, NCS Multistage Set Aug. 31 Election Deadline Ahead of Anticipated Sept. 1 Merger Close

Reuters
·
4 hours ago

Weatherford International - Co and NCS Multistage Set Aug 31, 2026 Election Deadline for Merger Consideration

THOMSON REUTERS
·
4 hours ago

Analysts’ Top Industrial Goods Picks: Napco Security Technologies (NSSC), QXO Inc (QXO)

TIPRANKS
·
6 hours ago

Top Midday Decliners

MT Newswires Live
·
6 hours ago

Alert Incorrectly Tagged to RPC Inc Withdrawn

Reuters
·
8 hours ago

RPC Acquires Peracidin® Product Line

THOMSON REUTERS
·
Yesterday

Why Is NAPCO Security Stock Soaring Monday?

Benzinga Earnings
·
Yesterday

Asian Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires Live
·
Yesterday

Enerya Enerji and TGS Dis Ticaret Declare Cash Dividends Effective August 25, 2026

TIPRANKS
·
Yesterday

Morning Movers: Regenxbio sinks following clinical hold on RGX-121

TIPRANKS
·
Yesterday

Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

MT Newswires Live
·
Yesterday

GOLDWAY EDU Completes Share Placement, Raising Approximately HK$4.4 Million Net

Stock News
·
Yesterday

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Dow Jones
·
Yesterday

Humacyte Says Phase 3 V012 Trial Shows ATEV Extends Catheter-Free Dialysis Time in Women

Reuters
·
Yesterday

Humacyte - Seeks to Add Dialysis Access as Second Approved Indication for Atev

THOMSON REUTERS
·
Yesterday

Humacyte - Supplemental Bla to be Supported by Three Phase 3 Studies of Atev

THOMSON REUTERS
·
Yesterday

Humacyte - to File Supplemental Bla with FDA for Atev in Dialysis Access in November 2026

THOMSON REUTERS
·
Yesterday